GTx, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other medical conditions. As of December 31, 2008, the Company is developing toremifene citrate, a selective estrogen receptor modulator (SERM), in two separate clinical programs in men. In addition the Company is also developing selective androgen receptor modulators (SARMs), with Merck and Co., Inc. (Merck). It is also developing GTx-758, an oral luteinizing hormone (LH), inhibitor for the treatment of advanced prostate cancer. In October 2008, Company announced the topline results of a Phase II clinical trial evaluating Ostarine in patients with cancer cachexia.